Steven Goldstein, MD
Internal Medicine · Clarksville, INNPI 1356306609
Payments from drug & device makers
Across 127 payments — averaging $12.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$213
- Pfizer$210
- Boehringer Ingelheim$197
- Amgen$160
- AstraZeneca$128
- Novo Nordisk$115
- plus $528 from 16 others
What the payments were for
- Food & beverage$1,545100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 19 | $213 |
| Pfizer | 31 | $210 |
| Boehringer Ingelheim | 7 | $197 |
| Amgen | 14 | $160 |
| AstraZeneca | 4 | $128 |
| Novo Nordisk | 11 | $115 |
| Merck | 15 | $115 |
| AbbVie(2 entities) | 5 | $73 |
| Amarin Pharma, Inc. | 4 | $71 |
| Supernus Pharmaceuticals, Inc. | 1 | $37 |
| Lilly USA, LLC | 3 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Viiv Healthcare Company | 1 | $23 |
| Genentech USA, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$125
How this compares
$1,551 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 335 | $1,348,537 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 99 | $382,561 |
| OzempicSemaglutide | 297 | $360,383 |
| EliquisApixaban | 328 | $296,181 |
| TivicayDolutegravir Sodium | 81 | $211,884 |
| Humira PenAdalimumab | 14 | $199,648 |
| JardianceEmpagliflozin | 216 | $199,028 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 37 | $195,042 |
| MounjaroTirzepatide | 101 | $122,283 |
| JulucaDolutegravir/Rilpivirine | 31 | $100,676 |
| PrezcobixDarunavir/Cobicistat | 41 | $100,207 |
| CabenuvaCabotegravir/Rilpivirine | 20 | $99,488 |
| DescovyEmtricitabine/Tenofov Alafenam | 47 | $97,497 |
| IsentressRaltegravir Potassium | 47 | $88,953 |
| RelistorMethylnaltrexone Bromide | 21 | $82,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Tivicay, Juluca, Cabenuva, Dovato | $23 | $838,055246 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Wegovy | $115 | $401,870322 claims |
| PfizerEliquis | $210 | $296,181328 claims |
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $34 | $226,706136 claims |
| Boehringer IngelheimJardiance, Tradjenta | $197 | $216,246232 claims |
| MerckIsentress, Isentress Hd, Pifeltro | $115 | $153,92482 claims |
| Johnson & JohnsonPrezcobix, Invega Sustenna | $213 | $138,47352 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $28 | $82,51721 claims |
| NovartisEntresto | $17 | $81,63879 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $128 | $59,35176 claims |
| AbbVieLinzess | $73 | $32,25355 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Clarksville
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.